We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

88 hedge funds and large institutions have $461M invested in BioCryst Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

75% more capital invested

Capital invested by funds: $264M → $461M (+$197M)

43% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $7.64M

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

17% more funds holding

Funds holding: 75 → 88 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
2.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
26
Increased
26
Reduced
21
Closed
13
Calls
$10.9M
Puts
$7.64M
Net Calls
+$3.26M
Net Calls Change
+$20K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$68.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.9M
3
State Street
State Street
Massachusetts
+$16.8M
4
CAM
Cormorant Asset Management
Massachusetts
+$9.6M
5
TAM
THB Asset Management
Connecticut
+$3.21M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$8.88M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.23M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.96M
4
TC
TFS Capital
Pennsylvania
-$3.8M
5
SGAM
Smith Group Asset Management
Texas
-$2.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Credit Suisse
Switzerland
$1.48M +$26.4K +2,475 +2%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$1.37M – – –
Northern Trust
28
Northern Trust
Illinois
$1.22M -$928 -87 -0.1%
EI
29
EAM Investors
California
$1.21M +$1.22M +114,548 New
AQR Capital Management
30
AQR Capital Management
Connecticut
$1.18M +$176K +16,500 +17%
USAA
31
United Services Automobile Association
Texas
$1.09M -$270K -25,370 -20%
ARTA
32
A.R.T. Advisors
New York
$1.06M +$1.07M +100,239 New
Deutsche Bank
33
Deutsche Bank
Germany
$985K +$772K +72,448 +349%
FSA
34
Franklin Street Advisors
North Carolina
$984K -$490K -46,000 -33%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$964K -$237K -22,236 -20%
Renaissance Technologies
36
Renaissance Technologies
New York
$958K +$965K +90,514 New
Bank of America
37
Bank of America
North Carolina
$892K -$120K -11,216 -12%
AL
38
Airain Ltd
Guernsey
$659K +$61.4K +5,755 +10%
SFM
39
Soros Fund Management
New York
$632K +$636K +59,700 New
Swiss National Bank
40
Swiss National Bank
Switzerland
$584K +$122K +11,400 +26%
RFC
41
Russell Frank Company
Washington
$581K +$762K +71,428 New
DC
42
Deere & Company
Illinois
$566K -$457K -42,826 -44%
SIM
43
Spark Investment Management
New York
$561K +$566K +53,100 New
ProShare Advisors
44
ProShare Advisors
Maryland
$479K +$206K +19,349 +75%
Commonwealth Equity Services
45
Commonwealth Equity Services
Massachusetts
$458K +$259K +24,300 +128%
PP
46
PDT Partners
New York
$423K -$545K -51,126 -56%
Wells Fargo
47
Wells Fargo
California
$418K +$143K +13,454 +52%
DekaBank Deutsche Girozentrale
48
DekaBank Deutsche Girozentrale
Germany
$386K +$389K +36,500 New
KIA
49
KCM Investment Advisors
California
$384K – – –
TD Asset Management
50
TD Asset Management
Ontario, Canada
$357K +$359K +33,700 New
1
2
3 4 5

BCRX Hedge Fund Activity: Q1 2014 in Review

88 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2014, worth a combined $461M — up 75% from $264M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BCRX positions and 13 closed out — a net gain of 13 holders — while 26 added to existing stakes and 21 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $68.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.88M.

  • 88 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2014, up from 75 in Q4 2013.
  • Funds reported $461M of BioCryst Pharmaceuticals stock for Q1 2014, up 75% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +13 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $68.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.88M sold.

Based on aggregated 13F filings for Q1 2014.